2023-06-08 08:08:43 ET
Clinical-stage biotech Annovis Bio ( NYSE: ANVS ) added ~12% pre-market Thursday after announcing that its Phase 3 trial for lead candidate buntanetap in Parkinson's disease (PD) reached full enrollment target "at a record pace."
After dosing the first patient in August, the placebo-controlled trial has enrolled 520 patients meeting the enrollment target within nine months since it began.
The trial designed to evaluate the effects of buntanetap for early PD in addition to standard care is currently underway in 67 sites in the U.S. and EU.
Annovis ( ANVS ) attributed its rapid enrollment rate to the early-stage results for buntanetap, indicating its efficacy and safety, and the pill's once-daily dosing regimen.
The company intends to conclude the trial in November and release its topline data by the end of 2023.
More on Annovis Bio
- Annovis gets US patent linked to buntanetap for neurodegenerative diseases
- Annovis: Making Sense Of The Interim Analysis
For further details see:
Annovis spikes 12% after Phase 3 enrollment update on Parkinson's disease drug